Evaluates inhaled tobramycin and colistin to improve symptoms in non-CF bronchiectasis patients, indicating potential benefits.
Introduction: The efficacy of inhaled antibiotics in Cyctic Fibrosis(CF) has been documented. There is less information on non CF patients, the 30% of whom is colonized with P.aeruginosa (Pa) Aim: To evaluate the effect of inhaled tobramycin (Bramitob, Chiesi) and Colistimethatesodium (Colistin Norma) in patients with non CF bronchiectasis and Pa in sputum. Methods: Twenty nine patients were studied (19 women), mean age 56.06 yr (24-80), with >10 4 CFU of Pa/ ml in sputum culture. Patients were randomized in 3 groups: tobramycin 300mgx2 (group A, 10 patients), colistin 1MUx2 (group B, 10 patients), N/S 0.9% 4ccx2 (group C, 9 patients). Administration was done through Pari LC Plus jet nebulizer for 4 weeks. Symptoms, sputum purulence and culture, spirometry and SaO2 were estimated before and after treatment. Results: Improvement was found in groups A and B compared to placebo regarding: a)Pa density (p= 0.003, p=0.008, p=0.08 for groups A, B and C respectively) b)breathlessness ,MRC scale (p=0.035, p=0.015, p=0.34) c)sputum volume (p=0.005, p=0.009, p=0.08) d)sputum purulence (8/10 group A, 10/10 group B, 0/9 group C). Differences in spirometry and SaO2 were not significant. Adverse events were reported in 4/10, 2/10 and 3/9 in group A, B and C respectively, not requiring discontinuation of treatment. Conclusions: Our data indicate that inhaled antibiotics, tobramycin and colistin may be effective in improving symptoms and reducing Pa load in bronchiectatic patients. Further investigation is necessary.
No takes yet. Share an insight, caveat, or question.
Dimakou et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: